Kevin Charles Gorman, Director at NEUROCRINE BIOSCIENCES INC (NBIX), sold 11,688 shares at $116.69 ($1.4M) on 2025-02-13, disclosed to the SEC on 2025-02-14.
Scheduled sale ($1.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $116.68 | 3,012 | $351K | 25.8% |
| 2 | $116.68 | 3,012 | $351K | 25.8% |
| 3 | $116.69 | 2,832 | $330K | 24.2% |
| 4 | $116.69 | 2,832 | $330K | 24.2% |
| Total | $116.68 avg | 11,688 | $1.4M | 100% |
| Filing → |
| NBIX | SELL | 2025-08-11 | $26.9M | — | Filing → |
| XNCR | SELL | 2025-06-16 | $29K | — | Filing → |
| NBIX | SELL | 2025-05-29 | $2.3M | — | Filing → |